JP5030947B2 - フラビウイルス感染の治療及び予防のための化合物及び方法 - Google Patents

フラビウイルス感染の治療及び予防のための化合物及び方法 Download PDF

Info

Publication number
JP5030947B2
JP5030947B2 JP2008510379A JP2008510379A JP5030947B2 JP 5030947 B2 JP5030947 B2 JP 5030947B2 JP 2008510379 A JP2008510379 A JP 2008510379A JP 2008510379 A JP2008510379 A JP 2008510379A JP 5030947 B2 JP5030947 B2 JP 5030947B2
Authority
JP
Japan
Prior art keywords
trans
methyl
amino
thiophene
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008510379A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008540463A (ja
JP2008540463A5 (cg-RX-API-DMAC7.html
Inventor
デニス，リアル
ポイソン，カール
ダス，サンジョイ・クマール
モトリナ，イリナ
レジ，ラビンドラ
ヤノポロス，コンスタンティン・ジー
チャン・チュン・コン，ラヴァル
Original Assignee
ヴァイロケム・ファーマ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァイロケム・ファーマ・インコーポレーテッド filed Critical ヴァイロケム・ファーマ・インコーポレーテッド
Publication of JP2008540463A publication Critical patent/JP2008540463A/ja
Publication of JP2008540463A5 publication Critical patent/JP2008540463A5/ja
Application granted granted Critical
Publication of JP5030947B2 publication Critical patent/JP5030947B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2008510379A 2005-05-13 2006-05-15 フラビウイルス感染の治療及び予防のための化合物及び方法 Expired - Fee Related JP5030947B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68048205P 2005-05-13 2005-05-13
US60/680,482 2005-05-13
PCT/CA2006/000786 WO2006119646A1 (en) 2005-05-13 2006-05-15 Compounds and methods for the treatment or prevention of flavivirus infections

Publications (3)

Publication Number Publication Date
JP2008540463A JP2008540463A (ja) 2008-11-20
JP2008540463A5 JP2008540463A5 (cg-RX-API-DMAC7.html) 2009-07-02
JP5030947B2 true JP5030947B2 (ja) 2012-09-19

Family

ID=37396165

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008510379A Expired - Fee Related JP5030947B2 (ja) 2005-05-13 2006-05-15 フラビウイルス感染の治療及び予防のための化合物及び方法

Country Status (16)

Country Link
US (3) US7569600B2 (cg-RX-API-DMAC7.html)
EP (3) EP1879879B1 (cg-RX-API-DMAC7.html)
JP (1) JP5030947B2 (cg-RX-API-DMAC7.html)
KR (1) KR20080016597A (cg-RX-API-DMAC7.html)
CN (2) CN101218224B (cg-RX-API-DMAC7.html)
AP (1) AP2007004245A0 (cg-RX-API-DMAC7.html)
AU (1) AU2006246227B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0610283A2 (cg-RX-API-DMAC7.html)
CA (1) CA2607359C (cg-RX-API-DMAC7.html)
EA (1) EA016071B1 (cg-RX-API-DMAC7.html)
ES (1) ES2415742T3 (cg-RX-API-DMAC7.html)
MX (1) MX2007014117A (cg-RX-API-DMAC7.html)
NZ (1) NZ563909A (cg-RX-API-DMAC7.html)
SG (1) SG161315A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006119646A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200709727B (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100851A2 (en) * 2001-06-11 2002-12-19 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
JP5030947B2 (ja) * 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
CN101568538B (zh) 2006-11-15 2012-09-05 Viro化学制药公司 用于治疗或预防黄病毒属感染的噻吩类似物
WO2008112159A2 (en) * 2007-03-12 2008-09-18 Merck & Co., Inc. Monocyclic anilide spirolactam cgrp receptor antagonists
PL2308514T3 (pl) 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
JP2010528051A (ja) 2007-05-23 2010-08-19 シガ・テクノロジーズ・インコーポレーテッド デング感染症の治療または予防のための抗ウイルス薬
GB0712393D0 (en) * 2007-06-26 2007-08-01 Smithkline Beecham Corp Compounds
CN103483251A (zh) 2007-12-19 2014-01-01 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
WO2010022238A2 (en) * 2008-08-21 2010-02-25 Health Research, Inc. Anti-flavivirus therapeutic
CA2750227A1 (en) 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
JP5327744B2 (ja) * 2009-03-13 2013-10-30 国立大学法人 鹿児島大学 ジフェニルメタン誘導体を有効成分とする抗ウイルス剤
TW201116525A (en) * 2009-07-21 2011-05-16 Gilead Sciences Inc Inhibitors of flaviviridae viruses
NZ598208A (en) 2009-09-09 2014-02-28 Gilead Sciences Inc Inhibitors of flaviviridae viruses
WO2011034962A2 (en) * 2009-09-16 2011-03-24 Calcimedica Inc. Compounds that modulate intracellular calcium
MX2012006026A (es) 2009-11-25 2012-08-15 Vertex Pharma Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
ES2543105T3 (es) * 2010-01-15 2015-08-14 Gilead Sciences, Inc. Inhibidores de virus flaviviridae
JP5868872B2 (ja) * 2010-01-15 2016-02-24 ギリアード サイエンシーズ， インコーポレイテッド フラビウイルス科ウイルスのインヒビター
UY33473A (es) 2010-06-28 2012-01-31 Vertex Pharma Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus
JP2013531011A (ja) * 2010-06-28 2013-08-01 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
CA2808291A1 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
WO2012083105A1 (en) 2010-12-17 2012-06-21 Cocrystal Discovery, Inc. Inhibitors of hepatitis c virus polymerase
US20130203706A1 (en) * 2011-06-28 2013-08-08 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
ES2561888T3 (es) 2011-07-13 2016-03-01 Gilead Sciences, Inc. Derivados de ácido tiofeno-2-carboxílico útiles como inhibidores de virus Flaviviridae
CN103059042B (zh) * 2011-10-18 2015-10-07 银杏树药业(苏州)有限公司 噻吩类衍生物及其在药学中的用途
AR088408A1 (es) 2011-10-21 2014-05-28 Abbvie Inc Metodos para el tratamiento de hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2013201406B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
CN103087052A (zh) * 2011-10-31 2013-05-08 上海壹志医药科技有限公司 噻吩衍生物及其药物用途
WO2014055142A1 (en) 2012-06-20 2014-04-10 Cocrystal Discovery, Inc. Inhibitors of hepatitis c virus polymerase
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
TWI731854B (zh) 2015-03-23 2021-07-01 美商共結晶製藥公司 Ｃ型肝炎病毒聚合酶之抑制劑
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN106467477A (zh) * 2016-08-26 2017-03-01 天津雅奥科技发展有限公司 一种合成化合物（1‑环丙基‑1‑氰基‑4‑环己酮）的新方法
WO2019217643A1 (en) 2018-05-09 2019-11-14 Cocrystal Pharma, Inc. Combination therapy for treatment of hcv
CR20200618A (es) 2018-06-19 2021-01-21 Novartis Ag Derivados de tetrahidrotienopiridina n-sustituidos y sus usos
CN110592172B (zh) * 2019-10-29 2021-05-28 华中农业大学 利用CRISPR/Cas9敲除文库技术筛选JEV抗性基因的方法与靶点
CN111518015A (zh) * 2020-05-20 2020-08-11 上海合全药物研发有限公司 一种叔丁基-8-氧亚基-2-氮杂螺[4.5]癸烷-2-甲酸基酯的制备方法
CN113861176B (zh) * 2021-09-28 2023-11-03 北京凯因格领生物技术有限公司 一种黄病毒抑制剂
EP4282862A1 (en) * 2022-05-25 2023-11-29 Irbm S.P.A. Flavivirus inhibitors
WO2024254161A2 (en) * 2023-06-05 2024-12-12 Celloram Inc. Inhibitors of fatty acid binding proteins (fabps), methods of use and methods of making

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076817A (en) * 1963-02-05 New j-amino-thiophene-z
DE1055007B (de) 1957-08-29 1959-04-16 Dr Hans Fiesselmann Verfahren zur Herstellung von 3-Aminothiophen-2-carbonsaeureestern und den entsprechenden freien Carbonsaeuren
US3470151A (en) 1966-05-17 1969-09-30 Beecham Group Ltd Furyl- and thienyl-penicillins and salts thereof
AU518216B2 (en) * 1977-09-06 1981-09-17 Hafslund Nycomed Pharma Aktiengesellschaft Thienothiazine derivatives
GB8627698D0 (en) 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
US4962101A (en) 1989-08-21 1990-10-09 Merck & Co., Inc. 2-(Heterocyclylalkyl)phenyl carbapenem antibacterial agents
JPH0748360A (ja) 1993-05-31 1995-02-21 Yoshitomi Pharmaceut Ind Ltd ビフェニルテトラゾール誘導体
EA001915B1 (ru) 1996-10-18 2001-10-22 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы серин-протеаз, в частности ns3 протеазы вируса гепатита c (hvc)
JP4000608B2 (ja) * 1996-11-07 2007-10-31 トヨタ自動車株式会社 水素製造充填装置および電気自動車
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
JP3455233B2 (ja) 1997-04-28 2003-10-14 テキサス・バイオテクノロジー・コーポレイシヨン エンドテリン介在障害治療用のスルホンアミド類
JP2002500650A (ja) 1997-05-23 2002-01-08 バイエル、コーポレイション Ｒａｆキナーゼ阻害剤
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
JP4344960B2 (ja) 1997-05-23 2009-10-14 バイエル、コーポレイション アリール尿素によるｐ３８キナーゼ活性の阻害
AU757072B2 (en) 1997-08-11 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptide analogues
DK1003775T3 (da) 1997-08-11 2005-05-30 Boehringer Ingelheim Ca Ltd Hepatitis C-inhibitorpeptider
ATE228119T1 (de) 1998-04-15 2002-12-15 Pfizer Prod Inc Heterocyclische carboxamide
EP0960882A1 (en) * 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
US6858223B2 (en) * 1998-06-23 2005-02-22 Altana Pharma Ag Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS)
ATE253061T1 (de) * 1998-06-29 2003-11-15 Iaf Biochem Int Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
ES2244204T3 (es) 1998-07-27 2005-12-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Derivados de dicetoacidos como inhibidores de polimerasas.
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
OA11599A (en) 1998-08-20 2004-08-23 Agouron Pharma Non-peptide GnRH agents, methods and intermediatesfor their preparation.
DE19903398A1 (de) 1999-01-29 2000-08-10 Hassan Jomaa Verwendung von Thiadiazolderivaten zur prophylaktischen und therapeutischen Behandlung von Infektionen
SI1165516T1 (sl) * 1999-03-12 2005-02-28 Boehringer Ingelheim Pharmaceuticals Inc. Heterociklična sečnina in sorodne spojine, uporabne kot protivnetna sredstva
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
JP2001010957A (ja) 1999-04-28 2001-01-16 Sankyo Co Ltd 肝障害の予防または抑制剤
DE19920247A1 (de) 1999-05-03 2000-11-16 Hassan Jomaa Arzneimittel mit einem Gehalt an Verbindungen mit einem Stickstoff-Sauerstoff-Heterocyclus als Wirkstoff und ihre Verwendung
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
EP1229010A1 (en) 1999-10-01 2002-08-07 Japan Energy Corporation Novel diarylamide derivatives and use thereof as medicines
KR20020058046A (ko) * 1999-11-29 2002-07-12 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 살충성 ｎ-헤테로아릴 알파-알콕시미노-카르복사미드
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
DE10002424A1 (de) * 2000-01-20 2001-07-26 Siemens Ag Di(het)arylaminothiophen-Derivate
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AU2002213048A1 (en) 2000-10-05 2002-04-15 Smith Kline Beecham Corporation Phosphate transport inhibitors
US7105565B2 (en) 2000-11-08 2006-09-12 Syngenta Crop Protection, Inc. Pyrrolcarboxamides and pyrrolcarbothioamides and their agrochemical uses
JP3889708B2 (ja) 2000-11-20 2007-03-07 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎トリペプチド阻害剤
US6892279B2 (en) * 2000-11-30 2005-05-10 Mosaid Technologies Incorporated Method and apparatus for accelerating retrieval of data from a memory system with cache by reducing latency
DE10061876A1 (de) * 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
BR0206614A (pt) 2001-01-22 2004-02-17 Merck & Co Inc Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto
AU2002252183A1 (en) 2001-03-06 2002-09-19 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
US6734207B2 (en) * 2001-04-20 2004-05-11 Parker Hughes Institute Cytotoxic compounds
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
US6713638B2 (en) * 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
CA2449999C (en) 2001-06-11 2012-07-31 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
WO2002100851A2 (en) * 2001-06-11 2002-12-19 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
EP1429759A4 (en) 2001-09-26 2004-12-15 Bristol Myers Squibb Co COMPOUNDS FOR TREATING HEPATITIS C VIRUS
ES2315430T3 (es) * 2001-10-04 2009-04-01 Smithkline Beecham Corporation Inhibidores de nf-kb.
AU2002348414B2 (en) 2001-10-24 2009-10-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
TWI281916B (en) * 2001-10-25 2007-06-01 Lilly Co Eli Antitumor compounds and methods
WO2003055479A1 (en) * 2001-12-21 2003-07-10 Consejo Superior De Investigaciones Cientificas Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3
US6835745B2 (en) * 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
DE10203122A1 (de) 2002-01-25 2003-07-31 Gruenenthal Gmbh Verfahren zur Herstellung von substituierten Acrylsäureestern bzw. deren Einsatz zur Herstellung von substituierten gamma-Aminosäuren
EP1497282A2 (en) 2002-04-11 2005-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4 protease
MXPA04010983A (es) 2002-05-06 2005-02-14 Genelabs Tech Inc Derivados de nucleosidos para tratar infecciones por el virus de la hepatitis c.
US7109354B2 (en) * 2002-05-28 2006-09-19 3-Dimensional Pharmaceuticals, Inc. Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
US7179836B2 (en) * 2002-09-20 2007-02-20 Smithkline Beecham Corporation Chemical compounds
CN100413861C (zh) 2002-12-10 2008-08-27 维勒凯姆制药股份有限公司 用于治疗或预防黄病毒感染的化合物
AU2003291885A1 (en) 2002-12-10 2004-06-30 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US20040192707A1 (en) 2002-12-10 2004-09-30 Laval Chan Chun Kong Compounds and methods for the treatment or prevention of Flavivirus infections
US7098241B2 (en) * 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
JP2006526011A (ja) 2003-04-11 2006-11-16 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ（特に、ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ）のインヒビター
TW200510391A (en) 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20050113566A1 (en) 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
AU2004247627A1 (en) 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US7345046B2 (en) 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
AU2004257288A1 (en) 2003-07-18 2005-01-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
TW201127828A (en) 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20050119189A1 (en) 2003-09-18 2005-06-02 Cottrell Kevin M. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
GB0324653D0 (en) 2003-10-22 2003-11-26 Syngenta Participations Ag Fungicides
DE10359791A1 (de) 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
EP1711515A2 (en) 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2006093518A2 (en) 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
FR2873692B1 (fr) 2004-07-29 2006-12-01 Univ Claude Bernard Lyon COMPOSITIONS CONTENANT, EN ASSOCIATION AVEC UN AGENT ANTIMICROBIEN, UN COMPOSE THIOPHENIQUE OU BENZOTHIOPHENIQUE DE FORMULE(I)PRESENTANT UNE ACTIVITE INHIBITRICE DE POMPE NorA
AU2005291918A1 (en) 2004-10-01 2006-04-13 Vertex Pharmaceuticals Incorporated HCV NS3-NS4A protease inhibition
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
DE102005028077A1 (de) 2004-12-22 2006-07-13 Aicuris Gmbh & Co. Kg Alkinyl-substituierte Thiophene
JP5030947B2 (ja) * 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
JP2006334109A (ja) 2005-06-01 2006-12-14 Matsushita Electric Works Ltd ヘアセット装置
CN101568538B (zh) 2006-11-15 2012-09-05 Viro化学制药公司 用于治疗或预防黄病毒属感染的噻吩类似物

Also Published As

Publication number Publication date
EP2543664A1 (en) 2013-01-09
CN101218224B (zh) 2013-05-08
CN101218224A (zh) 2008-07-09
HK1112910A1 (en) 2008-09-19
JP2008540463A (ja) 2008-11-20
EP2546246A2 (en) 2013-01-16
US20060276533A1 (en) 2006-12-07
US8158675B2 (en) 2012-04-17
ZA200709727B (en) 2008-11-26
AU2006246227B2 (en) 2011-04-28
KR20080016597A (ko) 2008-02-21
CA2607359A1 (en) 2006-11-16
ES2415742T3 (es) 2013-07-26
US20120164103A1 (en) 2012-06-28
US20100093775A1 (en) 2010-04-15
AP2007004245A0 (en) 2007-12-31
EA016071B1 (ru) 2012-01-30
SG161315A1 (en) 2010-05-27
EP1879879A1 (en) 2008-01-23
NZ563909A (en) 2011-10-28
EP1879879A4 (en) 2010-03-10
EP2546246A3 (en) 2013-04-24
CA2607359C (en) 2011-08-09
US7569600B2 (en) 2009-08-04
US8674118B2 (en) 2014-03-18
MX2007014117A (es) 2008-02-05
AU2006246227A1 (en) 2006-11-16
BRPI0610283A2 (pt) 2010-10-19
EP1879879B1 (en) 2013-03-27
EA200702493A1 (ru) 2008-04-28
WO2006119646A1 (en) 2006-11-16
CN102718744A (zh) 2012-10-10

Similar Documents

Publication Publication Date Title
JP5030947B2 (ja) フラビウイルス感染の治療及び予防のための化合物及び方法
JP5290186B2 (ja) フラビウイルス感染症の治療または予防用のチオフェン類似体
AU2011205048B2 (en) Compounds and methods for the treatment or prevention of flavivirus infections
HK1112910B (en) Compounds and methods for the treatment or prevention of flavivirus infections
HK1177453A (en) Compounds and methods for the treatment or prevention of flavivirus infections
HK1164291A (en) Thiophene analogues for the treatment or prevention of flavivirus infections
HK1176356A (en) Thiophene analogues for the treatment or prevention of flavivirus infections
HK1138569B (en) Thiophene analogues for the treatment or prevention of flavivirus infections
AU2013206705A1 (en) Thiophene analogues for the treatment or prevention of flavivirus infections
HK1182385A (en) Thiophene analogues for the treatment or prevention of flavivirus infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090515

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111107

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20111109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120306

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120406

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120601

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120626

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150706

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees